{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-009259","form_type":"8-K","ticker":"NUWE","cik":"0001506492","company_name":"Nuwellis, Inc.","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.311093+00:00","generated_at":"2026-06-18T17:48:53.312344+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nuwellis Q4 revenue up 42% YoY to $2.3M; net loss narrows to $1.9M","bullets":["Q4 revenue $2.3M (+42% YoY); full-year revenue $8.5M (+8% YoY). Gross margin 56.9% (+250 bps).","Net loss $1.9M ($5.00/share) vs $4.3M loss prior year; includes $2.6M other income from warrant revaluation.","Cash $18.3M, no debt; outstanding shares ~1.2M after reverse split and warrant exercises.","Entered exclusive U.S. license for SeaStar Medical's SCD for pediatric AKI; clinical data published supporting Aquadex.","Board increased inducement plan shares by 44,078 to 46,928 to attract talent."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-009259","json":"https://secwatch.observer/filing/0001140361-23-009259.json","markdown":"https://secwatch.observer/filing/0001140361-23-009259.md","text":"https://secwatch.observer/filing/0001140361-23-009259.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506492/000114036123009259/0001140361-23-009259-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506492/000114036123009259/brhc10049033_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T17:48:53.312344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ba7436d6bfd61bfe21c1c7bd93902844a7c437d","claim":"Nuwellis, Inc. reported the twelve months ended December 31, 2022 results: revenue $8.5 million.","evidence_excerpt":"Full year revenue of $8.5 million, an 8% increase over 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506492/000114036123009259/0001140361-23-009259-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the twelve months ended December 31, 2022"},{"label":"Revenue","value":"$8.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ca3406622cf656161874e75b15d87ad2c9fe49d3","claim":"Nuwellis, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $2.3 million, net income $1.9 million, EPS loss of $5.00 per basic and diluted common share.","evidence_excerpt":"Revenue for the fourth quarter of 2022 was $2.3 million, compared to $1.6 million in the prior-year period. Gross margin was 56.9% for the fourth quarter of 2022, compared to 54.4% in the prior-year period, an increase of 250 basis points, resulting from increased sales volume. Selling, general and administrative expenses for the fourth quarter of 2022 were $4.7 million, compared to $4.1 million in the prior-year period. The increase in SG&A was primarily due to higher professional service fees and variable compensation expense, balanced with continued spending vigilance. Fourth quarter research and development expenses were $1.2 million, compared to $1.1 million in the fourth quarter of 2021, reflecting a slight increase in product development expenses . Net loss for the fourth quarter of 2022 was $1.9 million, or a loss of $5.00 per basic and diluted common share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506492/000114036123009259/0001140361-23-009259-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$2.3 million"},{"label":"Net income","value":"$1.9 million"},{"label":"EPS","value":"loss of $5.00 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}